
Hemab Therapeutics Holdings, Inc. (($COAG)) has held its Q3 earnings call. Read on for the main highlights of the call. Hemab Therapeutics’ earnings call carried a clearly positive tone, with
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| COAG | Hemab Therapeutics Holdings, Inc. | 39.96 | 5.18 | 14.88% |
| Name | Price | % Change | |
|---|---|---|---|
| $39.96 | +14.88% |

Hemab Therapeutics Holdings, Inc. (($COAG)) has held its Q3 earnings call. Read on for the main highlights of the call. Hemab Therapeutics’ earnings call carried a clearly positive tone, with

“We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3

Hemab Therapeutics (COAG) announced the initiation of SOLARA, a pivotal Phase 3 trial evaluating sutacimig as a potential prophylactic treatment for people with Glanzmann thrombasthenia, or GT. The first participants

LifeSci Capital initiated coverage of Hemab Therapeutics (COAG) with an Outperform rating and $65 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

Hemab Therapeutics Holdings, Inc. (COAG) is scheduled to report 3rd quarter earnings on 11/10/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Hemab Therapeutics Holdings, Inc. to

JPMorgan analyst Joyce Zhou initiated coverage of Hemab Therapeutics (COAG) with an Overweight rating and $70 price target The firm says the company has an emerging pipeline of early to

Rodman & Renshaw initiated coverage of Hemab Therapeutics (COAG) with a Buy rating and $56 price target The firm cites sutacimig’s path to becoming the first approved prophylactic therapy in

Hemab Therapeutics (COAG) announced that the first healthy volunteer has been dosed in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy menstrual bleeding.

Wedbush analyst David Nierengarten raised the firm’s price target on Hemab Therapeutics (COAG) to $64 from $55 and keeps an Outperform rating on the shares. The firm notes the company

H.C. Wainwright raised the firm’s price target on Hemab Therapeutics (COAG) to $60 from $52 and keeps a Buy rating on the shares post the Q2 report. The firm says
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.